Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 8 of 45

Biologic DMARDs Included in the Comparative Effectiveness Review

The biologic disease-modifying anti-rheumatic drugs (DMARDs) that have been studied for treatment of rheumatoid arthritis and were included in the comparative effectiveness review are:

The biologic DMARDs that target tumor necrosis factor-alpha (TNF-α) include adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®), and infliximab (Remicade®).

Other biologic DMARDs included in the review target immune system components other than TNF-α. They are:

Abatacept (Orencia®): Its target of activity is CD28.
Anakinra (Kineret®): Its target of activity is interleukin 1. 
Rituximab (Rituxan®): Its target of activity is CD20.
Tocilizumab (Actemra®, RoActemra®): Its target of activity is the interleukin-6 receptor.